GYKI 53655, a 2,3-benzodiazepine, non-competitively protects cultured neurones against AMPA toxicity

European Journal of Pharmacology

Volumn 331, Issue 1, 1997, Pages 93-96

  Kovács, Attila D ^a   Szabó, Géza ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

AMPA receptor; AMPA receptor antagonism; GYKI 53655; NBQX (6 nitro 7 sulfamoyl benzo f quinoxaline 2,3 dione); Neuroprotection

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; 2,3 DIOXO 6 NITRO 7 SULFAMOYLBENZO(F)QUINOXALINE; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; BENZODIAZEPINE DERIVATIVE; NEUROPROTECTIVE AGENT; QUINOXALINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; EMBRYO; IN VITRO STUDY; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TELENCEPHALON; ANIMAL; BRAIN; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; SPRAGUE DAWLEY RAT;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BENZODIAZEPINES; BRAIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; NEUROPROTECTIVE AGENTS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA;

EID: 0030610176     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01046-7     Document Type: Article

References (23)

1. Bleakman, D., Ballyk, B.A., Schoepp, D.D., Palmer, A.J., Bath, C.P., Sharpe, E.F., Woolley, M.L., Bufton, H.R., Kamboj, R.K., Tarnawa, I., Lodge, D., 1996. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles. Neuropharmacology 35, 1689-1702.
2. Block, F., Schmitt, W., Schwarz, M., 1996. Pretreatment but not post-treatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats. J. Neurol. Sci. 139, 167-172.
3. Coyle, J.T., Puttfarcken, P., 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
4. Courtney, M.J., Enkvist, M.O.K., Åkerman, K.E.O., 1995. The calcium response to the excitotoxin kainate is amplified by subsequent reduction of extracellular sodium. Neuroscience 68, 1051-1057.
5. Danysz, W., Parsons, C.G., Bresink, I., Quack, G., 1995. Glutamate in CNS disorders. Drug News Perspect. 8, 261-276.
6. Dawson, R., Beal, M.F., Bondy, S.C., DiMonte, D.A., Isom, G.E., 1995. Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diseases. Toxicol. Appl. Pharmacol. 134, 1-17.
7. Donevan, S.D., Rogawski, M.A., 1993. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10, 51-59.
8. Gill, R., 1994. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 6, 225-256.
9. Hollmann, M., Heinemann, S., 1994. Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.
10. Kovács, A.D., Egyed, A., 1996. Protection against non-NMDA receptor-mediated excitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat. Neurobiology 4, 59-72.
11. Kovács, A.D., Szabó, G., 1997. Comparison of neuroprotective efficacy of competitive and non-competitive AMPA antagonists in vitro. Environ. Toxicol. Pharmacol. 3, 69-72.
12. Li, H., Buchan, A.M., 1993. Treatment with an AMPA antagonist 12 h following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab. 13, 933-939.
13. Lodge, D., Bond, A., O'Neill, M.J., Hicks, C.A., Jones, M.G., 1996. Stereoselective effects of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies. Neuropharmacology 35, 1681-1688.
14. May, P.C., Robison, P.M., 1993. GYKI 52466 protects against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci. Lett. 152, 169-172.
15. Nurse, S., Corbett, D., 1996. Neuroprotection after several days of mild, drug-induced hypothermia. J. Cereb. Blood Flow Metab. 16, 474-480.
16. Parsons, C.G., Gruner, R., Rozental, J., 1994. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466). Neuropharmacology 33, 589-604.
17. Patel, M., Day, B.J., Crapo, J.D., Fridovich, I., McNamara, J.O., 1996. Requirement for superoxide in excitotoxic cell death. Neuron 16, 345-355.
18. Sheardown, M.J., Nielsen, E.O., Hansen, A.J., Jacobsen, P., Honoré, T., 1990. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: A neuroprotectant for cerebral ischemia. Science 247, 571-574.
19. Sheardown, M.J., Suzdak, P.D., Nordholm, L., 1993. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia, even when delayed 24 h. Eur. J. Pharmacol. 236, 347-353.
20. 3H]GYKI 53405 to Xenopus brain membranes. Neuroreport 5, 93-94.
21. Tarnawa, I., Farkas, S., Berzsenyi, P., Pataki, A., Andrási, F., 1989. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 167, 193-199.
22. Tarnawa, I., Engberg, I., Flatman, J.A., 1990. GYKI 52466, an inhibitor of spinal reflexes is a potent quisqualate antagonist. In: Lubec, G., Rosenthal, G.A. (Eds.), Amino Acids: Chemistry, Biology and Medicine. Escom Science Publishers B.V., Leiden, pp. 538-546.
23. Vizi, E.S., Mike, Á., Tarnawa, I., 1996. 2,3-benzodiazepines (GYKI 52466 and analogs): Negative allosteric modulators of AMPA receptors. CNS Drug Rev. 2, 91-126.